文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

二氢吡啶类钙通道阻滞剂药物基因组学变异与临床结局的关联:32 000例英国生物银行队列分析

Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
PubMed 文献 · Br J Clin Pharmacol · 2022-10-06

该研究基于英国生物银行1990-2017年基层医疗中处方二氢吡啶类钙通道阻滞剂(dCCB)的32 360例受试者,分析23个药物基因组学变异与冠心病、心衰、慢性肾病、水肿及换药等结局的关联。其余变异关联不强或不一致。

要点

  • RYR3 rs877087 T等位基因携带者使用dCCB时心衰风险轻度升高(HR 1.13,95%CI 1.02-1.25)。
  • 若rs877087 T携带者能达到非携带者的治疗效果,心衰发生率可降低9.2%(95%CI 3.1-15.4)。
  • NUMA1 rs10898815与CYP3A5 rs776746增加dCCB换用其他降压药的可能性。

核心结论

  • NUMA1、CYP3A5和RYR3常见遗传变异与dCCB处方患者不良临床结局风险升高相关。
  • 尚需研究明确基于药物基因组学变异指导dCCB处方能否改善临床结局。

研究设计与样本

  • 研究为基于英国生物银行的社区队列分析,纳入1990-2017年基层医疗中处方dCCB的受试者最多32 360例。
  • 受试者首次处方dCCB时年龄40-79岁,共分析23个遗传变异。
  • 结局为冠心病、心衰、慢性肾病、水肿的新发诊断及换用其他降压药。

主要发现

  • 若rs877087 T等位基因携带者能达到非携带者的治疗效果,dCCB处方患者心衰发生率可降低9.2%(95%CI 3.1-15.4)。
  • 在dCCB处方前有心脏病史的2296例患者中,rs877087纯合子较CC变异型新发冠心病或心衰风险升高。
  • NUMA1 rs10898815和CYP3A5 rs776746增加换用其他降压药的可能性。
  • 其余变异与研究结局无强或一致关联。

临床怎么用

  • 对计划使用dCCB的患者,RYR3 rs877087、NUMA1 rs10898815和CYP3A5 rs776746或可提示心衰风险及换药可能性,但当前证据尚不足以常规指导处方。

局限性

  • RYR3 rs877087与心衰的关联经多重检验校正后不显著。
  • 研究为观察性队列,不能确立因果关系。
  • 药物基因组学知识库PharmGKB中已报告的关联支持证据较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmacogenetic variants impact dihydropyridine calcium-channel blockers (dCCBs; e.g., amlodipine) treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence. We aimed to estimate associations between reported pharmacogenetic variants and incident adverse events in a community-based cohort prescribed dCCB. METHODS: We analysed up to 32 360 UK Biobank participants prescribed dCCB in primary care (from UK general practices, 1990-2017). We investigated 23 genetic variants. Outcomes were incident diagnosis of coronary heart disease, heart failure (HF), chronic kidney disease, oedema and switching antihypertensive medication. RESULTS: Participants were aged 40-79 years at first dCCB prescription. Carriers of rs877087 T allele in RYR3 had increased risk of hazard ratio (HF 1.13: 95% confidence interval 1.02 to 1.25, P = .02). Although nonsignificant after multiple testing correction, the association is consistent with prior evidence. We estimated that if rs877087 T allele could experience the same treatment effect as noncarriers, the incidence of HF in patients prescribed dCCB would reduce by 9.2% (95% confidence interval 3.1 to 15.4). In patients with a history of heart disease prior to dCCB (n = 2296), rs877087 homozygotes had increased risk of new coronary heart disease or HF compared to CC variant. rs10898815 in NUMA1 and rs776746 in CYP3A5 increased likelihood of switching to an alternative antihypertensive. The remaining variants were not strongly or consistently associated with studied outcomes. CONCLUSION: Patients with common genetic variants in NUMA1, CYP3A5 and RYR3 had increased adverse clinical outcomes. Work is needed to establish whether outcomes of dCCB prescribing could be improved by prior knowledge of pharmacogenetics variants supported by clinical evidence of association with adverse events.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Türkmen D, Masoli JAH, Delgado J, et al. Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients. Br J Clin Pharmacol. 2022. PMID: 36134646. doi:10.1111/bcp.15541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。